TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02894658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipiFlow system
Description: LipiFlow System is an in-office FDA approved treatment that relieves meibomian gland obstruction through the use of heat and pulsatile pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Warm compresses
Description: Warm compresses will be applied to fellow eye and that eye will undergo daily treatment with eyelid scrubs using a warm wash cloth and no tears baby shampoo every morning and warm compresses on the eyelids for 5-10 minutes twice a day. Patients will be instructed on how to perform proper lid hygiene at the initial visit.
Study: NCT00806169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone and bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone and bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone and bevacizumab
Study: NCT04149002

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention Arm Weekly IP3 text messages
Description: Subjects will be provided with a pre and post intervention survey, in addition to a narrated Powerpoint presentation focusing on the logistics of their IP3. Subjects will also receive weekly automated text messages to encourage adherence to the need for their IP3.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Arm General pregnancy text messages
Description: Subjects will be given pre and post pre questionnaires, in addition to a narrated Powerpoint presentation about the Clinic. Subjects will also be sent weekly text messages with general pregnancy information.
Study: NCT03165175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prescription drug-abuse education smartphone application
Description: As a patient-centered prevention effort, this brief intervention in a mobile phone app format focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
Study: NCT01721343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Undergo telephonic monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Undergo telephonic monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone-based intervention
Description: Undergo telephonic monitoring

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case management
Description: Participate in an individualized conditioning program with an RCM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case management
Description: Participate in an individualized conditioning program with an RCM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Undergo enhanced usual care with an RCM and PCM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Participate in an individualized conditioning program with an RCM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Participate in an individualized conditioning program with an RCM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: management of therapy complications
Description: Undergo enhanced usual care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: assessment of therapy complications
Description: Undergo enhanced usual care
Study: NCT02879916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Inject 3ml of levobupavacaine into the stellate ganglion area

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Inject 3ml of NaCl 0.9% into the stellate ganglion area
Study: NCT03223493

Intervention type: OTHER
Intervention: No treatment given
Description: Completion of a questionnaire

Intervention type: OTHER
Intervention: No treatment given
Description: Completion of a questionnaire

Intervention type: OTHER
Intervention: No treatment given
Description: Completion of a questionnaire
Study: NCT03120728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel/ethinyl estradiol contraceptive vaginal ring
Description: Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel/ethinyl estradiol contraceptive vaginal ring
Description: Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etonogestrel/ethinyl estradiol contraceptive vaginal ring
Description: Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section.
Study: NCT01342952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day
Study: NCT03228394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Ganaxolone IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV
Study: NCT01423955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin zeta
Description: The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
Study: NCT00747539

Intervention type: DRUG
Intervention: Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)
Description: Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.

Intervention type: DRUG
Intervention: Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)
Description: Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
Study: NCT01752556

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diagnosis and therapeutic decision
Description: A conventional polysomnography will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 moths
Study: NCT04581863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse oximeter
Description: Patients will be prompted twice daily to text their oxygen saturation level after walking in place for 1 minute. If the oxygen saturation is \>3% lower than than the baseline first O2 sat measurement, or if it falls below an absolute level of 90%, the patient will receive an immediate call from the same on-call RN's for COVID Watch and undergo the same triage protocol .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: COVID Watch
Description: Enrolled patients receive text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID Watch
Description: Enrolled patients receive text-based assessments, two times a day for 14 days and escalates care to a nurse via telemedicine for any reported worsening of symptoms not severe enough to recommend going to the ED immediately.
Study: NCT01752556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diagnosis and therapeutic decision
Description: A home respiratory polygraphy will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 months
Study: NCT01515579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One single dose of 6.25 mg/mL administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: One single dose of 6.0 mg/mL administered subcutaneously
Study: NCT05697653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin-to-Skin contact.
Description: Skin to skin contact: It is the laying of the newborn in the prone position on the mother's bare chest with only a diaper on.
Study: NCT01963767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-020
Description: Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.~Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries\* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract\*~* Vaccinium angustifolium~Other Ingredients:~Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03828760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music listening
Description: Patients will be asked to either use their personal phones to listen to preferred music which is already on their device, or if they do not have a phone or other personal device capable of playing music of their choice, we will use a device (e.g. iPod) to load music of their choice. While in the waiting room, participants will listen to music through headphones/earphones, however they will need to remove their headphones/earphones during the initial consultation with the family physician (explaining risks, etc.), and resume listening to music through the phone speakers once in the examination room as patients will need to be able to hear instructions from the physician during the procedure.
Study: NCT00550342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 intravenously for 4 doses
Study: NCT00650598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg (two 20-mg tablets) loading dose by mouth on Day 1 followed by 20 mg twice daily (BID) on Days 2-6
Study: NCT05589532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic single-tooth prosthesis using PEEK
Description: A single tooth implant-supported fixed prosthesis using PEEK polymer in its composition delivered as definitive prosthesis.
Study: NCT00042289

Intervention type: DRUG
Intervention: darunavir/ritonavir dosage #3
Description: darunavir/ritonavir twice daily 900/100 mg b.i.d.
Study: NCT01070134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Behavioural Therapy (MIBT)
Description: The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).~The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PT (psychodynamic therapy)
Description: The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).~The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions.
Study: NCT01866748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
Study: NCT01042158

Intervention type: DRUG
Group type: OTHER
Intervention: tadalafil and ambrisentan upfront combination therapy
Description: tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
Study: NCT01133665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab and Lenalidomide
Description: The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
Study: NCT02587832

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HHHFNC
Description: Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: Bubble CPAP System.
Study: NCT00649285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg
Description: 100mg, single dose fed
Study: NCT00650598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days
Study: NCT03041649

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GT button change - Mic-Key
Description: After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GT button change - Mini One
Description: After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
Study: NCT04192279

Intervention type: DIAGNOSTIC_TEST
Intervention: lactate clearance
Description: Lactate clearance rate was monitored within 6 hours after admission
Study: NCT03015727

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT/TOMO
Description: intensity modulated radiation therapy or tomotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT/TOMO
Description: intensity modulated radiation therapy or tomotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: 2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
Study: NCT00649285

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macrobid® Capsules 100 mg
Description: 100mg, single dose fed
Study: NCT00375674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo PO for 1 year on schedule 4/2: 4 weeks on, 2 weeks off or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent
Study: NCT00912782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 200,000 IU once a week for 3 weeks
Study: NCT00042289

Intervention type: DRUG
Intervention: elvitegravir/cobicistat
Description: elvitegravir/cobicistat 150/150 mg q.d.

Intervention type: DRUG
Intervention: dolutegravir
Description: dolutegravir 50 mg q.d.

Intervention type: DRUG
Intervention: tenofovir alafenamide fumarate (TAF)
Description: TAF 25 mg q.d. without cobicistat or ritonavir boosting

Intervention type: DRUG
Intervention: TAF w/cobicistat
Description: TAF 10 mg q.d. with cobicistat

Intervention type: DRUG
Intervention: TAF w/cobicistat or ritonavir
Description: TAF 25 mg q.d. with cobicistat or ritonavir boosting

Intervention type: DRUG
Intervention: efavirenz
Description: efavirenz 600 mg q.d.

Intervention type: DRUG
Intervention: efavirenz
Description: efavirenz 600 mg q.d.
Study: NCT02938221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedical video-oculography system
Description: Telemedical video-oculography setup consisting of video goggles (EyeSeeCam, Interacoustics GmbH, Germany), a mobile telemedical workstation and an extended conferencing and remote control system (MEYTEC GmbH, Germany)
Study: NCT03165864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS TMPRSS6-Lrx
Description: Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline .9%
Study: NCT03931395

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey
Description: Will give patients and families included in the honey standard of care group 40 packets of hospital approved honey to implement in the tonsillectomy post-operative care of the child

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Patients will receive standard post operative medications per surgeon

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive standard post operative medications per surgeon
Study: NCT02718391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell vaccine
Description: The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
Study: NCT02867722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid HCl
Description: Drug will be administered to consented patients
Study: NCT00857584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release quetiapine (quetiapine XR)
Description: Flexible dose from 300 to 600 mg/d (combination of tablets of 50mg, 200mg and 300mg) oral, daily, 8 weeks length.~Quetiapine XR was initiated at 50 mg/day and titrated to 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and flexible doses of 300 to 600 mg/d from day 5 to the end of the study.
Study: NCT01376245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate/vilanterol
Description: Inhaled corticosteroid/long acting beta-agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT00446758

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.
Study: NCT04149847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inguinal hernia repair
Description: patients 18 years and above presenting with primary inguinal hernia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: inguinal hernia repair
Description: patients 18 years and above presenting with primary inguinal hernia
Study: NCT00857584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.~Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adequate mood stabilizer
Description: An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).